SCHEMBL1440137

SCHEMBL1440137

Nc1cccc(C2CCCN(C(=O)O)C2)c1

nearest known ligand 0.58

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
PARP14 Q460N5 2/20 0.46
PARP10 Q53GL7 1/20 0.46
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
HIF1A Q16665 1/20 0.45
HSD11B1 P28845 2/20 0.44
DRD3 P35462 1/20 0.44
TNKS O95271 1/20 0.44
PARP1 P09874 1/20 0.44
PROKR1 Q8TCW9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28218450 0.93 RAB9A (0.49) ALDH1A1PARP14PARP10LMNAHPGD
SCHEMBL4615095 0.84 NPC1 (0.45) ALDH1A1PARP14PARP10
SCHEMBL3312540 0.83 ALDH1A1 (0.62) ALDH1A1TSHRLMNAHPGDHIF1A
SCHEMBL1995415 0.82 ALDH1A1 (0.48) ALDH1A1TSHRLMNAHPGDHIF1A
SCHEMBL3737773 0.82 ALDH1A1 (0.48) ALDH1A1TSHRLMNAHPGDHIF1A
SCHEMBL1439746 0.81 PDE4B (0.51)
SCHEMBL21359167 0.80 PROKR1 (0.62) ALDH1A1TSHRLMNAHPGDHIF1A
SCHEMBL23123210 0.79 HDAC1 (0.47) ALDH1A1TSHRLMNAHPGDHIF1A
SCHEMBL14151219 0.78 HDAC1 (0.46) HSD11B1PROKR1
SCHEMBL14151217 0.78 HDAC1 (0.46) HSD11B1PROKR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101039904-B Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders ABBOTT GMBH & CO KG 2014-09-24 CN disclosed
EP-2473049-A1 BRUTON'S TYROSINE KINASE INHIBITORS Biogen Idec MA Inc. (US) 2012-07-11 EP disclosed
WO-2011029046-A1 BRUTON'S TYROSINE KINASE INHIBITORS BIOGEN IDEC MA INC. (US) 2011-03-10 WO disclosed
CN-101039904-A Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders ABBOTT GMBH & CO KG (DE) 2007-09-19 CN disclosed